ONC-PluReceptor NK cells with Epcoritamab and Tafasitamab and Lymphodepletion Chemotherapy for the Treatment of Recurrent or Refractory B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria

• Patients with R/R diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) with all of the following: * Failure of >/= 2 prior lines of therapy, or an autologous or allogeneic stem cell transplant * Prior failure of chimeric antigen receptor (CAR)-T or not eligible for CAR-T cells
• Tumor biopsy positive for CD19 or CD20 at >/= 1% by immunohistochemistry or flow cytometry
• Age 18-80 years
• Karnofsky performance status >/=60%
• Absolute neutrophil count >/= 500/mm^3
• Platelet count >/= 50,000/mm^3
• Serum creatinine clearance (CrCl) >/= 30 ml/min, estimated using the Cockcroft-Gault equation
• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) </=3 x upper limit of normal (ULN); bilirubin and alkaline phosphatase (ALP) </=2 x ULN). Patients with cancer involvement of the liver and elevation of ALT, AST, bilirubin, and/or ALP </= 5 x ULN are eligible, per principal investigator (PI) discretion
• Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin and volume) >/=50%
• Adequate cardiac function with left ventricular ejection fraction >/= 40%, and no uncontrolled arrhythmias or symptomatic cardiac disease
• If female of child-bearing potential, she must not be pregnant or breastfeeding and required to have a negative urine or serum pregnancy test prior to enrollment
• Female participants of non-childbearing potential must meet at least one of the following criteria: * Postmenopausal (no menses in greater than or equal to 12 consecutive months). * History of hysterectomy or bilateral salpingo-oophorectomy. * Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy). ** Subjects who are of childbearing potential, sexually active, and at risk of pregnancy must agree to use a highly effective method of contraception for the duration of the active treatment and at least 3 months post-completion of the study therapy. Highly effective methods of contraception include the following: * Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal ligation or hysterectomy, subject/partner post vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Men treated or enrolled in this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration. Men who are able to have children must use effective birth control while in the study. If the male participant fathers a child or suspects that he has fathered a child while in the study, he must immediately notify his doctor
• Agree to sign the consent to the long-term follow-up protocol PA17-0843 to fulfill the institutional responsibilities to various regulatory agencies

Exclusion Criteria

• Lymphoma in CR with no measurable sites of disease
• Major surgery < 4 weeks prior to first dose of study drug
• Any other severe or uncontrolled disease or condition that might increase the risk associated with study participation
• Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer
• Grade >/= 3 non-hematologic toxicity from prior therapy that has not improved to grade </= 2
• Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >/=10,000 copies/mL, or >/= 2,000 IU/mL), or hepatitis C (detectable viral load by hepatitis C virus [HCV] ribonucleic acid [RNA] polymerase chain reaction [PCR])
• Active infection requiring parenteral antibiotics
• HIV infection
• Treatment within prior 2 weeks with any anti-cancer agent, investigational or approved
• Active central nervous system (CNS) involvement (untreated parenchymal brain metastasis or positive cytology of cerebrospinal fluid)
• Life expectancy </= 6 months
• Active and uncontrolled neurological disorder
• Patients receiving systemic steroid therapy at the time of enrollment (physiological substitutive doses are allowed), or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment
• Patients receiving immunosuppressive therapy